Back
Speaker illustration

Doctor Patrick Moriarty

University of Kansas Medical Center, Kansas City (United States of America)

Professor of Medicine, The University of Kansas Medical Center in Kansas City, Kansas. Director of Clinical Pharmacology and the Atherosclerosis & Lipid-Apheresis Center. Doctorate in Medicine and Surgery at the University of Rome School of Medicine and Surgery in Italy. Residency in Internal Medicine and training in Clinical Pharmacology at the University of Kansas Medical Center. A fellow of the American College of Physicians, the American College of Cardiology, the European Society of Cardiology, and the National Lipid Association. He was the 2014-2015 president of the International Society for Apheresis. He reviews manuscripts for multiple scientific journals and is the associate editor for the Journal of Clinical Apheresis. Published over 150 peer-reviewed articles/chapters. His research activities include atherosclerosis, familial hypercholesterolemia, Lp(a), Lipid-apheresis, inflammation, dementia, and hemorhelogy. Operates the largest U.S. Lipid-apheresis program.

Presentations

Red cell distribution width as a predictor of cardiovascular events in high-risk patients with statin intolerance: post-hoc analysis of the CLEAR Outcomes trial

Event: ESC Congress 2024

Topic: Biomarkers

Session: The broad spectrum of cardiovascular risk

Access
Thumbnail

The change in HDL proteomics following lipid-apheresis therapy

Event: ESC Congress 2018

Topic: Lipids, Other

Session: Preventive cardiology / Lipids

Access
Thumbnail

Efficacy and Safety of Evolocumab Compared With Continued Lipoprotein Apheresis: Results of a Randomised, Controlled, Open-Label Study

Event: ESC Congress 2017

Topic: Lipids (Epidemiology and Prevention)

Session: Late-Breaking Science Posters

Access
Thumbnail

ESCAPE - Effect of alirocumab on the frequency of lipoprotein apheresis: a randomised Phase III trial

Event: ESC Congress 2016

Topic: Lipids

Session: Hot Line prevention and lipids

Access
Thumbnail

Pitavastatin lowers plasma levels of CoQ10 less than equipotent doses of rosuvastatin or atorvastatin

Event: ESC Congress 2016

Topic: Lipids

Session: Cardiovascular cell biology

Access
Thumbnail

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources